Skip to main content
SpringerLink
Log in

AEs of nusinersen, risdiplam and onasemnogene abeparvovec

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study Clinical Drug Investigation : 23 Nov 2023. Available from: URL: https://doi.org/10.1007/s40261-023-01320-4

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

AEs of nusinersen, risdiplam and onasemnogene abeparvovec. Reactions Weekly 1985, 6 (2023). https://doi.org/10.1007/s40278-023-50776-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-50776-x

Search

Navigation